PriceTargets.com logo

First Tracks Biotherapeutics - TRAX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $41.00
  • Forecasted Upside: -2.45%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$42.03 As of 07/27/2026 05:00 PM ET
▲ +6.51 (18.33%)

This chart shows the closing price for TRAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New First Tracks Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRAX

Analyst Price Target is $41.00
▼ -2.45% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for First Tracks Biotherapeutics in the last 3 months. The average price target is $41.00, with a high forecast of $54.00 and a low forecast of $30.00. The average price target represents a -2.45% upside from the last price of $42.03.

This chart shows the closing price for TRAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in First Tracks Biotherapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2026
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/21/2026BarclaysBoost TargetOverweight ➝ Overweight$40.00 ➝ $48.00
7/10/2026HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $44.00
7/8/2026HC WainwrightReiterated RatingBuy ➝ Buy$30.00
6/8/2026Wells Fargo & CompanyInitiated CoverageOverweight$30.00
6/8/2026Wells Fargo & CompanyInitiated CoverageOverweight$30.00
5/4/2026Piper SandlerInitiated CoverageOverweight$54.00
4/28/2026HC WainwrightInitiated CoverageBuy$30.00
4/28/2026HC WainwrightUpgradeStrong-Buy$30.00
4/27/2026Zacks ResearchUpgradeHold
4/24/2026WedbushInitiated CoverageOutperform$30.00
4/24/2026Leerink PartnersInitiated CoverageOutperform$46.00
4/23/2026JPMorgan Chase & Co.Initiated CoverageOverweight$31.00
4/22/2026BarclaysInitiated CoverageOverweight$40.00
4/21/2026UBS GroupInitiated CoverageBuy$45.00
(Data available from 7/28/2021 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2026
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2026

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

First Tracks Biotherapeutics

Read More

Today's Range

Now: $42.03
Low: $39.60
High: $46.45

50 Day Range

MA: $22.37
Low: $15.32
High: $42.03

52 Week Range

Now: $42.03
Low: $14.72
High: $46.45

Volume

2,592,007 shs

Average Volume

636,691 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of First Tracks Biotherapeutics?

The following sell-side analysts have issued stock ratings on First Tracks Biotherapeutics in the last twelve months: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Piper Sandler, UBS Group AG, Wall Street Zen, Wedbush, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for TRAX.

What is the current price target for First Tracks Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for First Tracks Biotherapeutics in the last year. Their average twelve-month price target is $41.00, suggesting a possible downside of 2.5%. Piper Sandler has the highest price target set, predicting TRAX will reach $54.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $30.00 for First Tracks Biotherapeutics in the next year.
View the latest price targets for TRAX.

What is the current consensus analyst rating for First Tracks Biotherapeutics?

First Tracks Biotherapeutics currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TRAX.

What other companies compete with First Tracks Biotherapeutics?

Other companies that are similar to First Tracks Biotherapeutics include Definium Therapeutics, Hyperion DeFi, PHAXIAM Therapeutics, LianBio and Adial Pharmaceuticals. Learn More about companies similar to First Tracks Biotherapeutics.